POU6F2 and colorectal carcinoma: We used orlistat, a FA synthase inhibitor, to decrease the lipid content in CRC cells overexpressing POU6F2-AS1; on the other hand, we used palmitic acid (PA) to increase the lipid content in CRC cells with POU6F2-AS1 knockdown.